Leerink Partners Upgrades Relmada Therapeutics to Outperform, Announces $8 Price Target
Benzinga Newsdesk 9 months ago
NewsUpgradesPrice TargetAnalyst Ratings
Leerink Partners analyst Andrew Berens upgrades Relmada Therapeutics (NASDAQ:RLMD) from Market Perform to Outperform and announces $8 price target.
Leerink Partners analyst Andrew Berens upgrades Relmada Therapeutics (NASDAQ:RLMD) from Market Perform to Outperform and announces $8 price target.